Novartis’ Ionis-partnered drug designed to lower levels of Lp (a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events ...

The month of September 2025 marked a low point for relations between the U.K. government and Big Pharma.  | September 2025 ...

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly ...

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a ...

Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...